Centessa Pharmaceuticals (STU:260) Long-Term Debt : €71.07 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals Long-Term Debt?

Centessa Pharmaceuticals's Long-Term Debt for the quarter that ended in Jun. 2024 was €71.07 Mil.

Centessa Pharmaceuticals's quarterly Long-Term Debt increased from Dec. 2023 (€69.42 Mil) to Mar. 2024 (€70.66 Mil) and increased from Mar. 2024 (€70.66 Mil) to Jun. 2024 (€71.07 Mil).

Centessa Pharmaceuticals's annual Long-Term Debt declined from Dec. 2021 (€67.00 Mil) to Dec. 2022 (€65.89 Mil) but then increased from Dec. 2022 (€65.89 Mil) to Dec. 2023 (€69.42 Mil).

Centessa Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for Centessa Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals Long-Term Debt Chart

Centessa Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

67.00

65.89

69.42

Centessa Pharmaceuticals Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Long-Term Debt	Get a 7-Day Free Trial											67.66	69.34	69.42	70.66	71.07

Centessa Pharmaceuticals (STU:260) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Centessa Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Centessa Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (STU:260) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

CNTA:USA 260:Germany

Address

1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT

Website

https://www.centessa.com

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Centessa Pharmaceuticals Headlines

No Headlines